Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has raised over 1.1 billion yuan ($151.7 million) in a Series C round of financing from domestic and overseas investors, according to a statement on Thursday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in